Straits Times Index
3,294.29 +28.34 (+0.87%) Nikkei
38,152.21 +78.23 (+0.21%) Hang Seng
18,946.97 +409.16 (+2.21%) FTSE 100
8,381.35 +27.30 (+0.33%) Bitcoin USD
62,780.21 +1,223.04 (+1.99%) CMC Crypto 200
1,349.68 +49.58 (+3.81%)
Collegium Pharmaceutical, Inc. (COLL)
After hours:
| Previous close | 38.06 |
| Open | 38.31 |
| Bid | 37.83 x 100 |
| Ask | 37.91 x 100 |
| Day's range | 37.60 - 38.60 |
| 52-week range | 20.83 - 40.95 |
| Volume | |
| Avg. volume | 422,145 |
| Market cap | 1.238B |
| Beta (5Y monthly) | 1.05 |
| PE ratio (TTM) | 29.35 |
| EPS (TTM) | 1.29 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 40.00 |
ZacksCollegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ZacksCollegium Pharmaceutical (COLL) Q1 Earnings and Revenues Lag Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -2.68% and 1.44%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireCollegium Reports First Quarter 2024 Financial Results
– Generated Q1’24 Net Revenue of $144.9 Million – – Delivered Q1’24 Record Belbuca® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year – – Achieved Q1’24 GAAP Net Income of $27.7 Million vs. Q1’23 GAAP Net Loss of $(17.4) Million – – Delivered Q1’24 Adjusted EBITDA of $92.4 Million, Up 5% Year-over-Year – – Board of Directors Authorized $35.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2024 Guidance – – Conference Call Scheduled for Today at 4:30 p.m.
